Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensive Lipid-Lowering vs Statin+Aspirin in Asymptomatic CAC
NCT06722521Phase 4Recruiting
- Sponsor
- Asan Medical Center
- Start
- Jul 2025
- Primary completion
- Jun 2032
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pitavastatin and ezetimibe in Coronary artery calcification (CAC) and atherosclerosis (2 arms), sponsored by Asan Medical Center. Primary endpoint: Major Adverse Cardiovascular Events at 48 months. Started Jul 2025; status: recruiting.
02
Drugs
pitavastatinezetimibe
03
Conditions
Coronary artery calcification (CAC)atherosclerosis
Beyond the preview
Go deeper on NCT06722521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06722521.